are an "emerging growth company" as defined under federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements.Investing in our Class A common stock involves significant risks.
in this prospectus give retroactive effect to the stock split and related amendment to our certificate of incorporation.Inovalon Holdings, Inc.Our CompanyWe are a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to
insight, reporting, and benchmarking to support multiple client business needs such as government-mandated data filings, financial planning, and compliance requirements.Our Competitive StrengthsWe believe that our operational and financial success is based on the following key strengths:Industry-Leading Analytics.We have demonstrated performance and leadership in disease and comorbidity identification
following table presents a reconciliation of net income to Adjusted EBITDA for each of the periods indicated:Three Months EndedDecember 31,Year EndedDecember 31,2013201420132014(estimated & unaudited)(estimated & unaudited)LowHighLowHigh(in thousands)Reconciliation of Net Income to Adjusted EBITDA:Net Income$5,735$13,100$14,100$32,718$65,000$66,000Depreciation and amortization4,4124,8004,90015,51719,80019,900Interest expense181,1001,200791,3001,400Interest (income)(3)——(9)——Provision for income taxes2,4399,5009,60019,65743,30043,400​​​​​​​​​​​​​​​​​​​​EBITDA12,60128,50029,80067,962129,400130,700Stock-based compensation4341,5001,7001,8422,8003,000Other non-comparable items (a)———1,565——Professional service fees (b)478——478800800​​​​​​​​​​​​​​​​​​​​Adjusted EBITDA$13,513$30,000$31,500$71,847$133,000$134,500​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​(a)Other
could have a material adverse effect on the market price of our Class A common stock;•if our existing clients do not renew their agreements with us, renew at lower fee levels, decline to purchase additional
our business, results of operations, and growth prospects;13Table of Contents•if our security measures fail or are breached and unauthorized access to a client's data is obtained, our services may be
Condition and Results of Operations," included elsewhere in this prospectus.Year Ended December 31,Nine MonthsEndedSeptember 30,20112012201320132014(in thousands, except per share data)Consolidated Statement of Operations Data:Revenue$239,685$300,275$295,798$231,264$271,622Expenses:Cost of revenue102,695101,188120,05494,86985,065Sales and marketing6,7526,7935,9524,5975,355Research and development14,85515,49921,19216,17117,376General and administrative63,18472,66180,63860,26662,920Depreciation and amortization11,22912,89915,51711,10515,012​​​​​​​​​​​​​​​​​Total operating expenses198,715209,040243,353187,008185,728​​​​​​​​​​​​​​​​​Income from operations40,97091,23552,44544,25685,894​​​​​​​​​​​​​​​​​Other income and (expenses):Interest income1011964Interest expense(62)(129)(79)(61)(209)​​​​​​​​​​​​​​​​​Income before taxes40,91891,11752,37544,20185,689Provision for income taxes15,99135,96219,65717,21833,836​​​​​​​​​​​​​​​​​Net income$24,927$55,155$32,718$26,983$51,853​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Basic net income per share$0.18$0.40$0.24$0.20$0.39​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted net income per share$0.18$0.40$0.24$0.20$0.38​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Weighted average shares of common stock outstanding:Basic137,865137,865135,305135,555133,640​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted138,855139,040136,375136,730135,835​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​19Table of ContentsYear Ended December 31,Nine MonthsEndedSeptember 30,20112012201320132014(in thousands, except percentages and statements of work)Other Financial Data and Key Metrics(1):Adjusted EBITDA(2)$57,526$108,105$71,847$58,333$103,059Adjusted EBITDA margin(2)24%36%24%25%38%MORE2Registry dataset metricsUnique patient count(3)69,91686,002109,46498,607118,932Medical event count(4)5,479,5996,379,2938,321,2367,560,8389,112,175Trailing 12 month Patient Analytics Months (PAM)(5)8,797,51410,822,67312,812,63012,272,28015,513,903Engaged patient population statements of work(6)227314356344540Data analytics and data-driven intervention revenue mix:Revenue from data analytics subscriptions(7)42.3%45.3%48.6%47.0%56.3%Revenue from data-driven intervention platform services(8):Fully automated processes1.5%4.2%4.3%4.8%7.1%Partially automated processes56.2%50.5%47.1%48.2%36.6%​​​​​​​​​​​​​​​​​57.7%54.7%51.4%53.0%43.7%December 31,September 30,20112012201320132014(in thousands)Consolidated Balance Sheet Data:Cash and cash equivalents$114,872$106,361$110,594$110,891$131,947Accounts receivable, net of allowances36,76462,89933,39843,23352,037Working capital131,676136,933130,562145,209156,446Property, equipment and capitalized software, net28,08934,17043,05040,56149,126Goodwill62,26962,26962,26962,26962,269Total assets262,922285,655269,746277,710317,345Long-term debt268168279203285,191Total liabilities33,81748,82638,01232,471340,706Total stockholders' equity (deficit)229,105236,829231,734245,239(23,361)(1)MORE2Registry dataset metrics, Trailing 12 month Patient Analytics Months (PAM), and Engaged patient population statements of work,
Factors that may affect the renewal rate for our services and our ability to sell additional services include:•the price, performance and functionality of our services;•the availability, price, performance and functionality of competing services;23Table of Contents•our clients' perceived ability to develop and perform the services that we offer using their internal resources;•our ability to develop complementary services;•our continued ability to access the data necessary to enable us to effectively develop and deliver new services to
of our top clients, or if one or more of these clients significantly decreases its use of our services, our business and operating results could be materially and adversely affected.24Table of ContentsIf we do not develop new services that are adopted by clients, or fail to provide high quality support services to our clients, our growth prospects, revenues and operating
ability to sell additional services to existing clients would suffer and our reputation with existing or potential clients would be harmed.We cannot assure you that we will be able to manage our growth effectively, which could have a material adverse effect on our business, results of operations and growth
business, results of operations and growth prospects.If our security measures fail or are breached and unauthorized access to a client's data is obtained, our services may be perceived as insecure, we may incur significant
effectiveness of our security measures could be harmed and we could lose sales and clients, which could have a material adverse effect on our business, operations, and financial results.Data protection, privacy and similar laws restrict access, use, and disclosure of information, and failure to comply with or adapt to changes in these laws could materially
certain types of services in the future.The information that we provide to our clients could be inaccurate or incomplete, which could harm our business reputation, financial condition, and results of operations.We aggregate, process, and analyze healthcare-related data and information for use by our clients.
substituting inferior or more costly technologies into our solutions, or have a material adverse effect on our business, financial condition, and results of operations.Our services could become subject to new, revised, or enhanced regulatory requirements in the future, which could result in increased costs, could delay or prevent our
introduction of new services, or could impair the function or value of our existing services, which could materially and adversely affect our results of operations and growth prospects.The healthcare industry is highly regulated on the federal, state, and local levels, and is subject to changing legislative,
and negatively impact our relationship with clients, which could have an adverse effect on our reputation, financial condition, and results of operations.We rely on agreements with third parties to provide certain services, goods, technology, and intellectual property rights necessary to enable us to implement some of our
Condition and Results of Operations," included elsewhere in this prospectus.Year Ended December 31,Nine MonthsEndedSeptember 30,20112012201320132014(in thousands, except per share data)Consolidated Statement of Operations Data:Revenue$239,685$300,275$295,798$231,264$271,622Expenses:Cost of revenue102,695101,188120,05494,86985,065Sales and marketing6,7526,7935,9524,5975,355Research and development14,85515,49921,19216,17117,376General and administrative63,18472,66180,63860,26662,920Depreciation and amortization11,22912,89915,51711,10515,012​​​​​​​​​​​​​​​​​Total operating expenses198,715209,040243,353187,008185,728​​​​​​​​​​​​​​​​​Income from operations40,97091,23552,44544,25685,894​​​​​​​​​​​​​​​​​Other income and (expenses):Interest income1011964Interest expense(62)(129)(79)(61)(209)​​​​​​​​​​​​​​​​​Income before taxes40,91891,11752,37544,20185,689Provision for income taxes15,99135,96219,65717,21833,836​​​​​​​​​​​​​​​​​Net income$24,927$55,155$32,718$26,98351,853​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Basic net income per share$0.18$0.40$0.24$0.20$0.39​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted net income per share$0.18$0.40$0.24$0.20$0.38​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Weighted average shares of common stock outstanding:Basic137,865137,865135,305135,555133,640​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Diluted138,855139,040136,375136,730135,835​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Other Financial Data:Adjusted EBITDA(1)$57,526$108,105$71,847$58,333$103,059Adjusted EBITDA margin(1)24%36%24%25%38%53Table of ContentsDecember 31,September 30,20112012201320132014(in thousands)Consolidated Balance Sheet Data:Cash and cash equivalents$114,872$106,361$110,594$110,891$131,947Accounts receivable, net of allowances36,76462,89933,39843,23352,037Working capital131,676136,933130,562145,209156,446Property, equipment and capitalized software, net28,08934,17043,05040,56149,126Goodwill62,26962,26962,26962,26962,269Total assets262,922285,655269,746277,710317,345Long-term debt268168279203285,191Total liabilities33,81748,82638,01232,471340,706Total stockholders' equity (deficit)229,105236,829231,734245,239(23,361)(1)We
following table presents a reconciliation of net income to Adjusted EBITDA for each of the periods indicated (dollars in thousands):Year Ended December 31,Nine MonthsEndedSeptember 30,20112012201320132014Reconciliation of Net Income to Adjusted EBITDA:Net income$24,927$55,155$32,718$26,983$51,853Depreciation and amortization11,22912,89915,51711,10515,012Interest expense621297961209Interest (income)(10)(11)(9)(6)(4)Provision for income taxes15,99135,96219,65717,21833,836​​​​​​​​​​​​​​​​​EBITDA$52,199$104,134$67,962$55,361$100,906Stock-based compensation3,7672,5601,8421,4081,340Other non-comparable items(a)1,5601,4111,5651,564—Professional service fees(b)——478—813​​​​​​​​​​​​​​​​​Adjusted EBITDA$57,526$108,105$71,847$58,333$103,059​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​(a)Other